

# Daniel Ricklin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/545563/publications.pdf>

Version: 2024-02-01

128  
papers

12,818  
citations

44042

48  
h-index

24232

110  
g-index

149  
all docs

149  
docs citations

149  
times ranked

12386  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement: a key system for immune surveillance and homeostasis. <i>Nature Immunology</i> , 2010, 11, 785-797.	7.0	2,990
2	Complement evasion by human pathogens. <i>Nature Reviews Microbiology</i> , 2008, 6, 132-142.	13.6	654
3	Complement-targeted therapeutics. <i>Nature Biotechnology</i> , 2007, 25, 1265-1275.	9.4	427
4	Complement in disease: a defence system turning offensive. <i>Nature Reviews Nephrology</i> , 2016, 12, 383-401.	4.1	427
5	Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms. <i>Journal of Immunology</i> , 2013, 190, 3831-3838.	0.4	412
6	Interactions between coagulation and complement—their role in inflammation. <i>Seminars in Immunopathology</i> , 2012, 34, 151-165.	2.8	393
7	Novel mechanisms and functions of complement. <i>Nature Immunology</i> , 2017, 18, 1288-1298.	7.0	364
8	Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense. <i>Immunological Reviews</i> , 2016, 274, 33-58.	2.8	313
9	The renaissance of complement therapeutics. <i>Nature Reviews Nephrology</i> , 2018, 14, 26-47.	4.1	305
10	Structure of complement fragment C3b–factor H and implications for host protection by complement regulators. <i>Nature Immunology</i> , 2009, 10, 728-733.	7.0	299
11	Complement in cancer: untangling an intricate relationship. <i>Nature Reviews Immunology</i> , 2018, 18, 5-18.	10.6	279
12	Clinical promise of next-generation complement therapeutics. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 707-729.	21.5	253
13	Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation. <i>Science</i> , 2010, 330, 1816-1820.	6.0	241
14	Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. <i>Journal of Immunology</i> , 2013, 190, 3839-3847.	0.4	209
15	Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. <i>Nature Immunology</i> , 2009, 10, 721-727.	7.0	205
16	Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. <i>European Journal of Clinical Investigation</i> , 2015, 45, 423-440.	1.7	178
17	Oligohis-tags: mechanisms of binding to Ni <sup>2+</sup> –NTA surfaces. <i>Journal of Molecular Recognition</i> , 2009, 22, 270-279.	1.1	177
18	Protection of host cells by complement regulators. <i>Immunological Reviews</i> , 2016, 274, 152-171.	2.8	173

#	ARTICLE	IF	CITATIONS
19	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014, 123, 2094-2101.	0.6	172
20	Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1042-1050.	6.6	163
21	A structural basis for complement inhibition by <i>Staphylococcus aureus</i> . <i>Nature Immunology</i> , 2007, 8, 430-437.	7.0	148
22	Compstatin: A Complement Inhibitor on its Way to Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 262-281.	0.8	139
23	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. <i>Journal of Immunology</i> , 2013, 190, 5712-5721.	0.4	137
24	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. <i>Immunobiology</i> , 2013, 218, 496-505.	0.8	129
25	Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. <i>EMBO Journal</i> , 2016, 35, 1133-1149.	3.5	123
26	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. <i>Blood</i> , 2017, 129, 970-980.	0.6	119
27	Progress and Trends in Complement Therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	0.8	107
28	Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 643-651.	3.6	106
29	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. <i>Journal of Immunology</i> , 2012, 189, 5442-5448.	0.4	100
30	Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. <i>Journal of Immunology</i> , 2014, 192, 6020-6027.	0.4	97
31	Recent developments in low molecular weight complement inhibitors. <i>Molecular Immunology</i> , 2009, 47, 185-195.	1.0	96
32	New milestones ahead in complement-targeted therapy. <i>Seminars in Immunology</i> , 2016, 28, 208-222.	2.7	92
33	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2015, 126, 891-894.	0.6	89
34	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. <i>Journal of Immunology</i> , 2011, 186, 4269-4277.	0.4	85
35	Characterization of Ehp, a Secreted Complement Inhibitory Protein from <i>Staphylococcus aureus</i> . <i>Journal of Biological Chemistry</i> , 2007, 282, 30051-30061.	1.6	84
36	Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. <i>Molecular Immunology</i> , 2017, 89, 10-21.	1.0	79

#	ARTICLE	IF	CITATIONS
37	Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17621-17626.	3.3	77
38	Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10948-10953.	3.3	77
39	Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology, 2018, 102, 89-119.	1.0	72
40	Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin. ACS Chemical Biology, 2011, 6, 753-760.	1.6	70
41	A Molecular Insight into Complement Evasion by the Staphylococcal Complement Inhibitor Protein Family. Journal of Immunology, 2009, 183, 2565-2574.	0.4	63
42	Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology, 2011, 48, 481-489.	1.0	62
43	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
44	Tipping the balance: intricate roles of the complement system in disease and therapy. Seminars in Immunopathology, 2021, 43, 757-771.	2.8	59
45	Complement Deficiency Promotes Cutaneous Wound Healing in Mice. Journal of Immunology, 2015, 194, 1285-1291.	0.4	58
46	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology, 2015, 220, 476-482.	0.8	58
47	Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology, 2016, 43, 238-249.	2.3	55
48	Cutting Edge: Members of the <i>Staphylococcus aureus</i> Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 2. Journal of Immunology, 2008, 181, 7463-7467.	0.4	54
49	The Extracellular Adherence Protein from <i>Staphylococcus aureus</i> Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase. Journal of Immunology, 2014, 193, 6161-6171.	0.4	51
50	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. Journal of Immunology, 2012, 189, 4797-4805.	0.4	50
51	Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials, 2013, 34, 985-994.	5.7	50
52	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology, 2015, 220, 993-998.	0.8	49
53	Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition, 2009, 22, 495-505.	1.1	48
54	Manipulating the mediator: Modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology, 2012, 217, 1057-1066.	0.8	44

#	ARTICLE	IF	CITATIONS
55	Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. <i>Seminars in Immunology</i> , 2016, 28, 285-291.	2.7	44
56	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. <i>Expert Review of Hematology</i> , 2014, 7, 583-598.	1.0	43
57	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. <i>PLoS ONE</i> , 2010, 5, e12889.	1.1	42
58	Therapeutic control of complement activation at the level of the central component C3. <i>Immunobiology</i> , 2016, 221, 740-746.	0.8	41
59	Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. <i>Biomaterials</i> , 2014, 35, 3688-3696.	5.7	40
60	The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. <i>Frontiers in Immunology</i> , 2021, 12, 662164.	2.2	40
61	Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7254-7264.	1.4	39
62	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. <i>Journal of Molecular Biology</i> , 2010, 402, 17-29.	2.0	39
63	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. <i>Immunobiology</i> , 2012, 217, 1097-1105.	0.8	39
64	Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1207-1217.	1.8	38
65	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. <i>Journal of Immunology</i> , 2016, 196, 866-876.	0.4	37
66	Therapeutic targeting of the complement system. <i>Nature Reviews Drug Discovery</i> , 2019, , .	21.5	37
67	Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. <i>Molecular Oral Microbiology</i> , 2016, 31, 3-17.	1.3	36
68	Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. <i>FASEB Journal</i> , 2013, 27, 2768-2776.	0.2	35
69	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. <i>Journal of Immunology</i> , 2016, 196, 4671-4680.	0.4	35
70	Electrostatic contributions drive the interaction between <i>Staphylococcus aureus</i> protein Efb and its complement target C3d. <i>Protein Science</i> , 2008, 17, 1894-1906.	3.1	34
71	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. <i>Haematologica</i> , 2019, 104, 919-928.	1.7	34
72	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. <i>Shock</i> , 2019, 51, 78-87.	1.0	34

#	ARTICLE	IF	CITATIONS
73	C1q binding to surface-bound IgG is stabilized by C1r <sub>2</sub> s <sub>2</sub> proteases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	32
74	Advances in Understanding the Structure, Function, and Mechanism of the SCIN and Efb Families of Staphylococcal Immune Evasion Proteins. Advances in Experimental Medicine and Biology, 2012, 946, 113-133.	0.8	31
75	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
76	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	4.0	31
77	From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 2022, 235, 108785.	1.4	30
78	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 503-511.	0.8	28
79	Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. Frontiers in Molecular Biosciences, 2017, 4, 13.	1.6	28
80	Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family. Journal of Biological Chemistry, 2012, 287, 628-640.	1.6	26
81	CMAp: Complement Map Database. Bioinformatics, 2013, 29, 1832-1833.	1.8	26
82	Comparative Epitope Mapping with Saturation Transfer Difference NMR of Sialyl Lewis <sup>x</sup> Compounds and Derivatives Bound to a Monoclonal Antibody. Journal of Medicinal Chemistry, 2005, 48, 6879-6886.	2.9	25
83	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. Journal of Immunology, 2013, 191, 3858-3866.	0.4	24
84	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology, 2015, 194, 3305-3316.	0.4	23
85	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, 32-35.	1.4	23
86	TMA: beware of complements. Blood, 2013, 122, 1997-1999.	0.6	21
87	Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. Journal of Immunology, 2017, 198, 3326-3335.	0.4	21
88	Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Molecular Immunology, 2008, 45, 3142-3151.	1.0	19
89	Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. Biosensors and Bioelectronics, 2009, 24, 3359-3364.	5.3	17
90	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 2020, 105, e57-e60.	1.7	17

#	ARTICLE	IF	CITATIONS
91	A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins. <i>Journal of Biological Chemistry</i> , 2013, 288, 2870-2881.	1.6	16
92	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. <i>Clinical Immunology</i> , 2020, 214, 108391.	1.4	16
93	Exploring the Complement Interaction Network Using Surface Plasmon Resonance. , 2007, 598, 260-278.		16
94	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. <i>Immunobiology</i> , 2016, 221, 1046-1057.	0.8	14
95	Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. <i>Clinical Immunology</i> , 2016, 162, 37-44.	1.4	14
96	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. <i>Frontiers in Immunology</i> , 2017, 8, 1586.	2.2	14
97	Conjugation to Albuminâ€Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. <i>ChemMedChem</i> , 2014, 9, 2223-2226.	1.6	13
98	Complement therapeutics. <i>Seminars in Immunology</i> , 2016, 28, 205-207.	2.7	12
99	Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 367-378.	2.0	12
100	A Potent Mimetic of the Siglecâ€8 Ligand 6â€™â€Sulfoâ€Sialyl Lewis<sup>x</sup>. <i>ChemMedChem</i> , 2020, 15, 1706-1719.	1.6	11
101	Progress and trends in complement therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	0.8	11
102	Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 482-485.	0.7	10
103	Intracellular C4BPA Levels Regulate NF-ïB-Dependent Apoptosis. <i>IScience</i> , 2020, 23, 101594.	1.9	10
104	Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 301-313.	0.8	9
105	Attenuation of <i>Staphylococcus aureusâ€™</i> Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. <i>Journal of Immunology</i> , 2015, 195, 3946-3958.	0.4	9
106	Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. <i>Frontiers in Immunology</i> , 2021, 12, 615748.	2.2	9
107	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1041-1042, 19-26.	1.2	8
108	â€Stealthâ€™ corporate innovation: an emerging threat for therapeutic drug development. <i>Nature Immunology</i> , 2019, 20, 1409-1413.	7.0	7

#	ARTICLE	IF	CITATIONS
109	A sweet spot to control complement-induced inflammation. <i>Nature Medicine</i> , 2012, 18, 1340-1341.	15.2	6
110	Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. <i>International Journal of Computational Biology and Drug Design</i> , 2018, 11, 90.	0.3	6
111	Preformed mediators of defense "Gatekeepers enter the spotlight. <i>Immunological Reviews</i> , 2016, 274, 5-8.	2.8	4
112	Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. <i>British Journal of Pharmacology</i> , 2020, 178, 2802-2822.	2.7	4
113	Selective Monovalent Galectin-8 Ligands Based on Lactoylgalactoside. <i>ChemMedChem</i> , 2022, 17, .	1.6	4
114	Complement & disease: out of the shadow into the spotlight. <i>Seminars in Immunopathology</i> , 2021, 43, 755-756.	2.8	3
115	Correction: Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. <i>Journal of Immunology</i> , 2012, 188, 6425-6425.	0.4	2
116	Identification of complement-targeting peptides using phage-display libraries. <i>Molecular Immunology</i> , 2008, 45, 4180-4181.	1.0	1
117	A flow-through optical sensor system for label-free detection of proteins and DNA. , 2009, , .		1
118	A novel complement evasion mechanism of <i>Staphylococcus aureus</i> using Efb. <i>Molecular Immunology</i> , 2007, 44, 3926.	1.0	0
119	Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from <i>Staphylococcus aureus</i> . <i>Molecular Immunology</i> , 2008, 45, 4114-4115.	1.0	0
120	Characterization of the interactions between C3b and complement regulators. <i>Molecular Immunology</i> , 2010, 47, 2259-2259.	1.0	0
121	Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. <i>Molecular Immunology</i> , 2010, 47, 2222-2222.	1.0	0
122	Diversity in the C3b contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.. <i>Journal of Biological Chemistry</i> , 2012, 287, 9329.	1.6	0
123	Preface. <i>Immunobiology</i> , 2012, 217, 1025.	0.8	0
124	Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique. <i>Immunobiology</i> , 2012, 217, 1140.	0.8	0
125	Complement in action: An analysis of patent trends from 1976 through 2011. <i>Immunobiology</i> , 2012, 217, 1157-1158.	0.8	0
126	Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern. <i>Immunobiology</i> , 2012, 217, 1160.	0.8	0

#	ARTICLE	IF	CITATIONS
127	On the conformational flexibility of C3b: A molecular insight into activation and transformation of a major complement effector. <i>Immunobiology</i> , 2012, 217, 1192.	0.8	0
128	Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. <i>Blood</i> , 2012, 120, 370-370.	0.6	0